文献速递临床试验与 GCP基础与转化研究

慢病毒珠蛋白基因治疗联合减低强度预处理治疗成人β地中海贫血:一项1期试验

Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial.
PubMed 文献 · Nat Med · 2022-01-03

该1期试验报告了4例输血依赖型成人β地中海贫血患者接受减低强度预处理后输注TNS9.3.55慢病毒珠蛋白载体转导的自体CD34+细胞,随访6-8年。未发生意外安全问题,基因标记稳定但水平低,2例患者输血需求减少但未达输血独立;中等克隆扩增与癌症相关基因附近整合相关,提示需谨慎监测携带珠蛋白载体的患者。

要点

  • 4例输血依赖型成人β地中海贫血患者接受减低强度预处理后输注慢病毒珠蛋白载体转导的自体CD34+细胞,随访6-8年。
  • 未发生意外安全问题,造血基因标记非常稳定但水平低,2例患者输血需求减少但未达输血独立。
  • 中等克隆扩增与癌症相关基因附近整合相关,提示珠蛋白载体在干/祖细胞中可能存在非红系活性,需谨慎监测。

核心结论

  • 非清髓性预处理可实现持久的干细胞植入,但有效治疗需要最低的CD34+细胞转导水平。
  • 中等克隆扩增与癌症相关基因附近整合相关,提示珠蛋白载体在干/祖细胞中可能存在非红系活性,需谨慎监测携带珠蛋白载体的患者。

研究设计与样本

  • 1期临床试验(NCT01639690),4例输血依赖型成人β地中海贫血患者接受减低强度预处理后输注TNS9.3.55慢病毒珠蛋白载体转导的自体CD34+细胞,随访6-8年。
  • 主要终点为减低强度预处理后输注产品的安全性和耐受性,监测插入性突变和复制 competent 慢病毒的产生;次要终点为基因修饰自体CD34+细胞的植入、转导β-珠蛋白基因的表达和移植后输血需求。

主要发现

  • 预处理和细胞产品输注期间未发生意外安全问题。
  • 造血基因标记非常稳定但水平低,2例患者输血需求减少,但未达到输血独立。
  • 中等克隆扩增与癌症相关基因附近整合相关,提示珠蛋白载体在干/祖细胞中可能存在非红系活性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

β-Thalassemias are inherited anemias that are caused by the absent or insufficient production of the β chain of hemoglobin. Here we report 6-8-year follow-up of four adult patients with transfusion-dependent β-thalassemia who were infused with autologous CD34+ cells transduced with the TNS9.3.55 lentiviral globin vector after reduced-intensity conditioning (RIC) in a phase 1 clinical trial ( NCT01639690) . Patients were monitored for insertional mutagenesis and the generation of a replication-competent lentivirus (safety and tolerability of the infusion product after RIC-primary endpoint) and engraftment of genetically modified autologous CD34+ cells, expression of the transduced β-globin gene and post-transplant transfusion requirements (efficacy-secondary endpoint). No unexpected safety issues occurred during conditioning and cell product infusion. Hematopoietic gene marking was very stable but low, reducing transfusion requirements in two patients, albeit not achieving transfusion independence. Our findings suggest that non-myeloablative conditioning can achieve durable stem cell engraftment but underscore a minimum CD34+ cell transduction requirement for effective therapy. Moderate clonal expansions were associated with integrations near cancer-related genes, suggestive of non-erythroid activity of globin vectors in stem/progenitor cells. These correlative findings highlight the necessity of cautiously monitoring patients harboring globin vectors.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Boulad F, Maggio A, Wang X, et al. Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial. Nat Med. 2022. PMID: 34980909. doi:10.1038/s41591-021-01554-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。